BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefin

Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% d

Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829

ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors,

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the anal

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). Wh

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale,

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 20

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE

Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metab

Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Co

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analys

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof

This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just rep

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZ

Truist Securities analyst Danielle Brill maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,0

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and rai

I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2

The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technica

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease;

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy

 – At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients,

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analys

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

Truist Securities analyst Danielle Brill initiates coverage on Maze Therapeutics (NASDAQ:MAZE) wi

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raise

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Mizuho analyst Salim Syed initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Outperform

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the

Wells Fargo analyst Sadia Rahman initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Ove

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raise

Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small m

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ: MAZE) with a Overweight and ra

HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Bu

Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy

BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the